Le Lézard

News by subject: TRI

13 december 2023

05:12
Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug...

05:00
Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the most...

05:00
Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the...

04:52
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the...

03:47
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled,...

03:30
Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in...


12 december 2023

18:40
Clover Biopharmaceuticals, Ltd.?(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the...

16:05
BIOLASE, Inc. , the global leader in dental lasers, today announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists. The trial, led by an...

12:09
Johnson & Johnson announced today the first data from the Phase 3 PERSEUS study highlighting significant clinical...

12:00
? Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients ? ? 63% overall response rate; responses observed across...

12:00
Patients with newly diagnosed multiple myeloma (MM) who received daratumumab...

12:00
Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who...

12:00
Stem cell transplantation is a potentially curative treatment for sickle cell disease (SCD), but it is not feasible for most people, often due to a lack of suitable donors or the inability to tolerate the...

12:00
Movano Health , a pioneer in health technology, today announced that following the successful results of its recent blood pressure clinical trial it will be holding in person demonstrations of live waveforms at both the 2024 CES Show in Las Vegas...

12:00
Patients with relapsed or refractory mantle cell lymphoma (MCL) who received ibrutinib in combination with venetoclax experienced significantly better...

11:00
A new study published in The Journal of Nutrition shows daily consumption of prunes may reduce inflammation markers connected to bone signaling pathways and reduce the effects of bone loss among postmenopausal women....

11:00
Particles for Humanity has received approval from the Institutional Review Board (IRB) at the University of Wisconsin-Madison in the United States to begin a human absorption study of PFH-VAP, a stable form of vitamin A. The study is designed to...

10:57
~ First study to demonstrate rapid and sustained absorption of NDS1C epinephrine nasal spray compared to epinephrine intramuscular autoinjector, while offering higher and more sustained therapeutic plasma levels ~ ~ Study also found that NDS1C was...

10:30
The global infection prevention market is estimated to be over US$ 40,845.2 million in 2024. Between 2024 and 2034, the market is predicted...

10:00
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today reported that the first subjects have been dosed in a Phase 1 clinical study of orally administered PLX-4545, a potent and selective molecular glue...

09:00
BillionToOne (BTO), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is pleased to announce a global collaboration with Janssen Research & Development, LLC, a Johnson & Johnson company...

09:00
Foresight Diagnostics, the leader in ultra-sensitive liquid biopsy MRD detection, announced multiple studies that consistently demonstrated higher clinical sensitivity and prognostic accuracy of Foresight Diagnostic's...

08:50
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual...

08:30
Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the publication of a scientific manuscript in the internationally recognized scientific journal, Molecular...

08:30
Lucid Diagnostics Inc. ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. ( "PAVmed"), today announced that three manuscripts providing interim results from the...

08:00
MAPS Public Benefit Corporation ("MAPS PBC"), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced the submission of a new...

08:00
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage...

08:00
Curis, Inc. , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS...

07:30
Freenome, a privately held company developing multiomics blood tests for early cancer detection, today announced the initiation of its PROACT LUNG study and provided an update on its lung cancer research, including the ongoing Vallania study. The...

07:26
Scinai Immunotherapeutics Ltd. , a biopharmaceutical company focused on development of inflammation and immunology biological products, is pleased to announce today successful preclinical trial results of its innovative anti?IL?17 VHH antibody...

07:22
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for...

07:00
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a Phase 2 clinical-stage biotechnology company, today announced positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a...

05:00
Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California from December 9-12. The data showcased updated results of...

03:00
ISA Pharmaceuticals B.V. (ISA), a clinical-stage immunotherapy company, today announced positive anti-tumor response...


11 december 2023

21:51
During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster...

20:45
Johnson & Johnson announced today an...

20:41
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (APG-2575), one of...

19:30
Eli Lilly and Company today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies....

19:30
HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years post-treatmentLong-term data continues to show a one-time...

19:30
Johnson & Johnson announced today new patient-reported outcomes (PRO) from the Phase 3 CARTITUDE-4 study of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) demonstrated clinically meaningful improvements in...

18:30
Imugene Ltd ("Imugene") , a clinical stage immuno-oncology...

18:00
Nektar Therapeutics announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting demonstrating...

16:06
New research in the December 2023 issue of JNCCN?Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for...

16:05
Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe...

14:59
Vascarta Inc. ("Vascarta") announced new research findings presented at the American Society of Hematology meeting in San Diego show that a novel transdermal preparation of curcumin from Vascarta reduced pain in humanized mice which suffer with the...

14:30
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class...

12:27
Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for...

10:54
ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options.A preliminary analysis of data in the phase 1b part of the ELEVATE...

10:54
Detailed results from SURMOUNT-4, which showed Zepboundtm (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in...

09:30
Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that the Company presented a poster at the 2023 San Antonio Breast...